{"id":228753,"title":"Guidance to Establish Equivalence or Relative Potency of Safety and Efficacy of a Second Entry Short-Acting Beta2-Agonist Metered Dose Inhaler (MDI) [Health Canada, 1999] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-19","captureTimestamp":"2025-04-19T00:18:22.478000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/guidance-establish-equivalence-relative-potency-safety-efficacy-second-entry-short-acting-beta2-agonist-metered-dose-inhaler.html?wbdisable=false","snippet":"Guidance to Establish Equivalence or Relative Potency of Safety and Efficacy of a Second Entry Short-Acting Beta2-Agonist Metered Dose Inhaler (MDI) [Health Canada, 1999] - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du…","rawSnapshotUrl":"/api/snapshots/raw/228753","browseUrl":"https://replay.healtharchive.ca/job-1/20250419001822/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/guidance-establish-equivalence-relative-potency-safety-efficacy-second-entry-short-acting-beta2-agonist-metered-dose-inhaler.html?wbdisable=false#ha_snapshot=228753","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}